NCT01623349 2021-02-10Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerDana-Farber Cancer InstitutePhase 1 Completed118 enrolled
NCT01237067 2019-12-17Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s CancersNational Institutes of Health Clinical Center (CC)Phase 1 Completed77 enrolled
NCT01650376 2018-03-23Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian CancerSwedish Medical CenterPhase 1/2 Unknown52 enrolled